Fibrocell Science’s investigational gene therapy FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) has received…
Articles by Alice Melao
Fibrocell Science and Castle Creek Pharmaceuticals are partnering to further develop the investigational gene therapy FCX-007 for…
Patients with recessive dystrophic epidermolysis bullosa (RDEB), particularly those with delayed puberty, have a higher risk of osteoporosis —…
The care and management of a 6-month-old baby with epidermolysis bullosa (EB) simplex during surgery for a corneal transplant was…
Krystal Biotech has completed the construction of its new manufacturing facility Ancoris, which will support the clinical and commercial…
After an interim analysis of a Phase 3 trial testing Amryt Pharma’s investigational therapy AP101 in epidermolysis bullosa (EB) patients,…
The EB Research Partnership (EBRP) and Epidermolysis Bullosa Medical Research Foundation (EBMRF) granted $900,000 to Fibrocell, a…
The commonly used antibiotic gentamicin (brand name Garamycin) can reverse the effects of about 80% of genetic mutations affecting the LAMB3…
Menlo Therapeutics’ investigative therapy serlopitant seems to effectively reduce itch in patients with epidermolysis bullosa, according to results…
A rare case of autoimmune-driven epidermolysis bullosa (EB) was described in a patient who also had an undiagnosed mild…
Amryt Pharma’s lead investigative therapy AP101, developed to reduce the time it takes for skin wounds to close, is…
Krystal Biotech plans to file an investigational new drug (IND) application for its lead therapy candidate KB103 for the treatment…